Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomic Predictors of Decitabine Response in AML/MDS
NCT01687400Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Washington University School of Medicine. Started Feb 2013; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01687400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01687400.